Confusion about testosterone and prostate cancer still drives unnecessary fear—and sometimes drives men toward unmonitored underground use. Modern evidence focuses on treating diagnosed hypogonadism, not chasing “high T” for performance.
What the trials suggest
The TRAVERSE cardiovascular outcomes trial in hypogonadal men with increased cardiovascular risk found that testosterone therapy did not show greater major adverse cardiac events than placebo over a median ~33 months—while emphasizing careful patient selection and monitoring.
For prostate safety, longitudinal data in treated hypogonadal men without a history of prostate cancer have not shown the simplistic “T causes aggressive cancer” story. Guidelines still require:
- Baseline PSA and digital rectal exam when clinically appropriate
- Monitoring PSA velocity and urology referral for red flags
- Avoiding treatment in untreated high-grade prostate cancer
Physiologic vs. supraphysiologic
Replacing testosterone to mid-normal physiologic ranges under supervision differs from supraphysiologic cycles used in sport doping—which carry distinct hematologic, lipid, and behavioral risks. FDA labeling and Endocrine Society guidance target the former.
Takeaway
Get symptoms and labs interpreted in context of sleep apnea, obesity, medications, and head injury history (when relevant). If therapy starts, it is a long-term monitoring relationship, not a one-time prescription.
This article is educational and not medical advice. Diagnosis and treatment decisions belong to you and your licensed clinician. If you have urgent symptoms, call emergency services or your local crisis line.